Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

ConditionDry Eye
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNeuro-Ophthalmology of Texas

About this trial

patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye

Eligibility criteria

Qualifiers

Age18 yr or older Diagnosis of neuro-ophthalmic condition Clinical diagnosis of dry eye disease OSDI score of 23 or greater at baseline Objective sign present Indicated for VEVYE prior to enrollment Ability and willingness to complete study visits and questionnaires

Disqualifiers

Patients with a corneal ulcer Use of another cyclosporine or lifitegrast product within 30 days of baseline Ocular surgery within 30 prior to baseline Active ocular infection or severe ocular surface condition unrelated to DED Contact lens wearers ( must be off contacts for 30 days and the duration of trial) Any condition that prevents compliance or informed consent Subjects with severe scarring / zero sensitivity

Trial design

Treatments tested in this trial

  • Cyclosporine ophthalmic solution 0.1%

Treatment groups

50 Participants
are divided into 2 treatment groups

Locations

1
Neuro Ophthalmology of TX77074, HoustonTexas, United States

Sponsors and collaborators

Neuro-Ophthalmology of Texas

Lead sponsor

Harrow Inc

Collaborator